Switch to injectable cabotegravir–rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial
Source: View publication →
In virologically suppressed adolescents living with HIV in sub-Saharan Africa, switching to long-acting injectable cabotegravir-rilpivirine every 8 weeks was superior to daily oral standard-of-care therapy for maintaining virological suppression over 96 weeks.
Key Findings
Study Design
Study Limitations
Clinical Significance
Switching to an every-8-week long-acting injectable cabotegravir-rilpivirine regimen offers superior virological suppression compared to standard daily oral ART in virologically suppressed adolescents living with HIV. Given the profound adherence challenges, pill fatigue, and stigma faced by this demographic, this LAI regimen provides a transformative, adherence-sparing maintenance option that could significantly improve long-term clinical outcomes.
Historical Context
Historically, adolescents living with HIV have experienced poorer virological outcomes than adults, largely driven by suboptimal adherence to daily oral therapy secondary to pill fatigue and stigma. While long-acting injectable cabotegravir-rilpivirine was previously established as a safe and effective maintenance therapy in adults (via trials like ATLAS and FLAIR), robust efficacy data in adolescents—particularly in sub-Saharan Africa, which bears the overwhelming majority of the pediatric HIV burden—have been lacking. The LATA trial is a landmark study as it not only establishes the efficacy of this injectable regimen in an adolescent population but also demonstrates its superiority over daily oral therapy, validating the hypothesis that removing the burden of daily adherence yields substantial clinical benefits in this vulnerable group.
Guided Discussion
High-yield insights from every perspective
What are the respective drug classes and mechanisms of action of cabotegravir and rilpivirine, and why is an injectable formulation particularly advantageous for the adolescent population?
Key Response
Cabotegravir is an integrase strand transfer inhibitor (INSTI) that prevents viral DNA integration into the host genome. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds reverse transcriptase. Adolescents face unique psychosocial barriers to daily oral adherence; a bi-monthly injection removes the daily pill burden, improving long-term virologic suppression.
Before initiating a patient on long-acting cabotegravir-rilpivirine, what specific historical and laboratory criteria must be met, particularly regarding prior treatment failures and current viral load?
Key Response
Patients must be virologically suppressed (usually HIV RNA under 50 copies/mL) on a stable regimen with no history of treatment failure, and no known or suspected viral resistance to either NNRTIs or INSTIs. Residents must verify these criteria to safely transition patients without risking rapid development of dual-class resistance.
Given the high background prevalence of NNRTI resistance mutations in sub-Saharan Africa, how do the LATA trial findings impact the risk-benefit analysis of using rilpivirine in this specific demographic, and what pharmacokinetic considerations exist for adolescents?
Key Response
Rilpivirine has a lower genetic barrier to resistance compared to second-generation INSTIs. While mutations like K103N do not profoundly affect rilpivirine, others like Y181C do. Fellows must consider if baseline proviral DNA genotyping is necessary or feasible. Pharmacokinetically, adolescents undergo rapid growth, requiring careful monitoring to ensure drug trough levels remain therapeutic over the 8-week dosing interval.
The LATA trial demonstrated superiority despite being designed as a non-inferiority trial. How should we interpret this superiority in the context of standard-of-care oral therapy, and what system-level infrastructure changes are required to implement bi-monthly injections in resource-limited clinics?
Key Response
The superiority likely stems from the adherence advantage of the injectable formulation over 96 weeks rather than superior intrinsic antiviral potency. For attendings and clinic directors, the challenge lies in implementation: managing the cold chain, tracking missed injection visits, and transitioning clinic workflows from pharmacy-dispensed oral medications to nurse-administered intramuscular injections.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
In an open-label non-inferiority trial that subsequently claims superiority, what statistical and methodological biases must be evaluated regarding the intention-to-treat versus per-protocol analyses, and how might the open-label design influence dropout rates in the standard-of-care arm?
Key Response
Open-label trials risk performance bias. Patients in the standard-of-care arm might have lower adherence due to the disappointment of not receiving the novel injectable, artificially inflating the relative efficacy of the intervention arm. A rigorous critique evaluates whether the superiority was driven by biological efficacy or artifactual standard-of-care drop-offs, and whether the non-inferiority margin was appropriately pre-specified.
As an editor evaluating this manuscript, how would you scrutinize the handling of missing data and delayed injection windows over the 96-week follow-up, particularly concerning how virologic failure was adjudicated if a participant missed their 8-week injection window?
Key Response
The FDA Snapshot algorithm strictly categorizes missing data. In an injectable trial, managing the pharmacokinetic tail of delayed injections is crucial. A seasoned reviewer would flag how delayed injections were tracked, whether they led to unrecognized resistance, and if loss-to-follow-up rates were differential between the injection and oral arms, which could threaten internal validity.
Based on the LATA trial finding of superiority at 96 weeks, should WHO guidelines elevate long-acting cabotegravir-rilpivirine from an alternative to a preferred optimization regimen for virologically suppressed adolescents in sub-Saharan Africa, and what programmatic feasibility factors must be weighed?
Key Response
Current WHO guidelines heavily rely on dolutegravir-based daily oral regimens. Demonstrating superiority in maintenance of suppression over 96 weeks provides high-certainty evidence for adolescents. However, the committee must weigh this efficacy against programmatic costs, cold chain requirements, and healthcare worker burden in low- and middle-income countries before universally upgrading the recommendation.
Clinical Landscape
Noteworthy Related Trials
ATLAS Trial
Tested
Long-acting injectable cabotegravir and rilpivirine every 4 weeks
Population
Virologically suppressed adults with HIV-1
Comparator
Continuation of current daily oral ART
Endpoint
Proportion of participants with HIV-1 RNA >= 50 copies/mL at week 48
ATLAS-2M Trial
Tested
Long-acting injectable cabotegravir and rilpivirine every 8 weeks
Population
Virologically suppressed adults with HIV-1
Comparator
Injectable cabotegravir and rilpivirine every 4 weeks
Endpoint
Proportion of participants with HIV-1 RNA >= 50 copies/mL at week 48
FLAIR Trial
Tested
Long-acting injectable cabotegravir and rilpivirine every 4 weeks
Population
Previously untreated (ART-naive) adults with HIV-1
Comparator
Daily oral dolutegravir-abacavir-lamivudine
Endpoint
Proportion of participants with HIV-1 RNA >= 50 copies/mL at week 48
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis